John K. Buolamwini

4.8k citations
75 papers · 3.1k indexed · 1 hit paper · h-index 29
Topics
Adenosine and Purinergic Signaling (18 papers)Cancer-related Molecular Pathways (14 papers)HIV/AIDS drug development and treatment (13 papers)
Partner nations
United StatesChinaCanada

In The Last Decade

John K. Buolamwini

75 papers receiving 3.0k citations

Hit Papers

Molecular Cloning, Characterization, and Expression in Es...19972026200620161997200400600

Peers

John K. Buolamwini
Comparison fields: 5 of 129
  • Molecular Biology 1.9k
  • Organic Chemistry 755
  • Oncology 728
  • Computational Theory and Mathematics 286
  • Infectious Diseases 280
Replace Daniel Zaharevitz with:
Daniel Zaharevitz United States
Haiying Chen United States
Daniel A. Bachovchin United States
Guoqiang Dong China
Tanaji T. Talele United States
Thomas O’Brien United States
Daniel F. Ortwine United States
Masami Otsuka Japan
Daniel Martinez Molina Sweden
Louis Malspeis United States
John K. Buolamwini relative to Daniel Zaharevitz United States Daniel Zaharevitz's profile →
Citations per field
00.5×1.5×
Daniel Zaharevitz · 1×
Citations per year

Countries citing papers authored by John K. Buolamwini

Since Specialization
Citations

This map shows the geographic impact of John K. Buolamwini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John K. Buolamwini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John K. Buolamwini more than expected).

Fields of papers citing papers by John K. Buolamwini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John K. Buolamwini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John K. Buolamwini. The network helps show where John K. Buolamwini may publish in the future.

Co-authorship network of co-authors of John K. Buolamwini

This figure shows the co-authorship network connecting the top 25 collaborators of John K. Buolamwini. A scholar is included among the top collaborators of John K. Buolamwini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John K. Buolamwini. John K. Buolamwini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 21
3 16
4 81
5 17
6 92
7 26
8 100
9 33
10 29
11 15
12 45
13 115
14
Novel anticancer agents : strategies for discovery and clinical testing
7
15 96
16 16
17 1
18 47
19 21
20 80

About John K. Buolamwini

John K. Buolamwini is a scholar working on Physiology, Oncology and Virology, having authored 75 papers that have together received 3.1k indexed citations. Recurring topics across this work include Adenosine and Purinergic Signaling (18 papers), Cancer-related Molecular Pathways (14 papers) and HIV/AIDS drug development and treatment (13 papers). The work is most often cited by research in Physiology (201 citations), Virology (147 citations) and Molecular Biology (1.9k citations). John K. Buolamwini has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Shantaram Kamath, Francis Ali‐Osman, Jia-Xi Mao, Gamil R. Antoun, Haregewein Assefa, Shivaputra A. Patil, Raymond F. Schinazi, Tino W. Sanchez, Nouri Neamati and Amol Gupte. Their work appears in journals such as Journal of Biological Chemistry, Nature Communications and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026